Log in

NASDAQ:ONCYOncolytics Biotech Stock Price, Forecast & News

$1.86
-0.05 (-2.62 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.85
Now: $1.86
$1.93
50-Day Range
$1.86
MA: $2.17
$2.66
52-Week Range
$0.35
Now: $1.86
$6.02
Volume333,447 shs
Average Volume505,022 shs
Market Capitalization$75.29 million
P/E RatioN/A
Dividend YieldN/A
Beta2.5
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCY
CUSIPN/A
CIKN/A
Phone403-670-7377

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-24,960,000.00

Miscellaneous

EmployeesN/A
Market Cap$75.29 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive ONCY News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.

Oncolytics Biotech (NASDAQ:ONCY) Frequently Asked Questions

How has Oncolytics Biotech's stock been impacted by COVID-19 (Coronavirus)?

Oncolytics Biotech's stock was trading at $1.74 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ONCY stock has increased by 6.9% and is now trading at $1.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Oncolytics Biotech?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oncolytics Biotech.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Oncolytics Biotech.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech, Inc. (NASDAQ:ONCY) released its quarterly earnings data on Friday, May, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.01. View Oncolytics Biotech's earnings history.

What price target have analysts set for ONCY?

4 Wall Street analysts have issued 1-year target prices for Oncolytics Biotech's stock. Their forecasts range from $6.00 to $9.00. On average, they anticipate Oncolytics Biotech's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 294.3% from the stock's current price. View analysts' price targets for Oncolytics Biotech.

Has Oncolytics Biotech been receiving favorable news coverage?

Media coverage about ONCY stock has been trending negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncolytics Biotech earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Oncolytics Biotech.

Are investors shorting Oncolytics Biotech?

Oncolytics Biotech saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,780,000 shares, an increase of 18.7% from the May 31st total of 1,500,000 shares. Based on an average daily trading volume, of 966,600 shares, the days-to-cover ratio is presently 1.8 days. Currently, 6.9% of the company's stock are sold short. View Oncolytics Biotech's Current Options Chain.

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include VBI Vaccines (VBIV), AzurRx BioPharma (AZRX), Vaxart (VXRT), Nokia Oyj (NOK), Outlook Therapeutics (OTLK), Inovio Pharmaceuticals (INO), Amplify Energy (AMPY), Amplify Energy (AMPY), Amarin (AMRN) and Sorrento Therapeutics (SRNE).

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the following people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look, Chief Financial Officer
  • Mr. Michael Moore, VP of Investor Relations & Corp. Communications
  • Dr. Rita Laeufle, Chief Medical Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

How do I buy shares of Oncolytics Biotech?

Shares of ONCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONCY stock can currently be purchased for approximately $1.86.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of $75.29 million. The company earns $-24,960,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is www.oncolyticsbiotech.com.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.